tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 296 are a BUY (85.55%), 49 are a HOLD (14.16%), 1 are a SELL (0.29%).
Analyst Robyn Karnauskas, currently employed at TRUIST, carries an average stock price target met ratio of 51.09% that have a potential upside of 39.9% achieved within 304 days.
Robyn Karnauskas’s has documented 706 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 08-Jan-2025.
Analyst best performing recommendations are on NCNA (NUCANA PLC).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$214
$4.99 (2.39%)
$221
1 months ago
(03-Feb-2025)
22/24 (91.67%)
$23.86 (12.55%)
449
Buy
$217
$7.99 (3.82%)
$211
1 months ago
(03-Feb-2025)
0/3 (0%)
$26.86 (14.13%)
Buy
$220
$10.99 (5.26%)
$195
1 months ago
(03-Feb-2025)
11/12 (91.67%)
$29.86 (15.70%)
342
Hold
$190
$-19.01 (-9.10%)
$200
1 months ago
(03-Feb-2025)
15/15 (100%)
$-0.14 (-0.07%)
259
Buy
$215
$5.99 (2.87%)
$205
1 months ago
(03-Feb-2025)
10/13 (76.92%)
$24.86 (13.07%)
327
Which stock is Robyn Karnauskas is most bullish on?
Which stock is Robyn Karnauskas is most reserved on?
What Year was the first public recommendation made by Robyn Karnauskas?
